Clinical Trial

Danicopan PMS in Korea

Recruiting
View on ClinicalTrials.gov →
Summary
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
Protocol Amendment History 4 changes
notable Enrollment increased: 8 -> 27 participants 2026-08-15
notable Trial sites reduced: 5 -> 2 locations 2026-06-30
critical Recruitment opened 2026-04-18
notable Trial sites expanded: 0 -> 4 locations 2026-04-18
Trial Details
NCT Number NCT07457151
Lead Sponsor AstraZeneca
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 27 participants
Start Date 2026-04-10
Primary Completion 2028-06-27 (estimated)
Study Completion 2028-06-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-14